Zhou Avery, Ho Sabrina, Vickers Aroucha
Kirk Kerkorian School of Medicine, Las Vegas, NV, USA.
Department of Neurology, Valley Hospital Medical Center, Las Vegas, NV, USA.
Saudi J Ophthalmol. 2024 Jan 6;38(1):34-40. doi: 10.4103/sjopt.sjopt_74_23. eCollection 2024 Jan-Mar.
Eculizumab, a monoclonal antibody against complement C5, is a novel therapy to treat refractory myasthenia gravis (MG). The present review was undertaken to study the role of eculizumab in MG. This includes the drug's mechanism, pharmacokinetics, clinical trial findings, tolerability, side effects, safety, dosage, administration, and cost. An English-language search for relevant items was undertaken using Embase and PubMed from 1946 to present. Clinical trial registries/databases and websites were also searched for relevant data. Keywords were eculizumab and MG. The present review found 103 articles after initial screening. Current data support eculizumab as an effective, safe, and tolerable drug in cases of refractory MG. However, its cost can prevent it from being widely accessible to a majority of the general population.
依库珠单抗是一种抗补体C5的单克隆抗体，是治疗难治性重症肌无力（MG）的一种新型疗法。本综述旨在研究依库珠单抗在重症肌无力中的作用。这包括该药物的作用机制、药代动力学、临床试验结果、耐受性、副作用、安全性、剂量、给药方式和成本。使用Embase和PubMed对1946年至今的相关英文文献进行了检索。还检索了临床试验注册库/数据库和网站以获取相关数据。关键词为依库珠单抗和重症肌无力。本综述在初步筛选后共找到103篇文章。目前的数据支持依库珠单抗在难治性重症肌无力病例中是一种有效、安全且耐受性良好的药物。然而，其成本可能使其无法被大多数普通人群广泛使用。
